YOLFTbeta
Alector Inc

Alector Inc

ALEC · NASDAQ · Healthcare / Biotechnology

2.54USD+0.09 (+3.67%)

Price History

Full chart

Market Stats

Previous Close2.45
Open2.59
Day Range2.30 – 2.59
52-Week Range1.09 – 3.40
Volume1.80M
Market Cap217.73M
P/E (TTM)0.00
Forward P/E8.47
EPS-1.03
Dividend Yield0.00%
Beta0.65
50-Day Avg1.97
200-Day Avg1.98

About

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Arnon Rosenthal Ph.D.
  • Employees103
  • Headquarters131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080, USA
  • Websitehttps://www.alector.com

Leadership

  • Dr. Arnon Rosenthal Ph.D.Co-Founder, CEO & Director · b. 1956
  • Mr. Neil Berkley M.B.A., M.S.CFO & Chief Business Officer · b. 1974
  • Ms. Katie HoganSenior Director of Corporate Communication & Investor Relations
  • Ms. Danielle Pasqualone J.D., Ph.D.General Counsel
  • Ms. Clare Hunt M.B.A.Chief People & Places Officer
  • Dr. Hua Long DABT, Ph.D.Senior VP & Head of Research
  • Dr. Caiyan Li Ph.D.Head of Clinical Development & Data Science
  • Dr. Eric Brown Ph.D.Director of Antibody Discovery & Protein Engineering

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue416.00K3.73M27.68M21.22M21.10M207.09M133.62M97.06M100.56M21.05M
Growth (%)-+797.84%+641.02%-23.33%-0.57%+881.54%-35.48%-27.36%+3.60%-79.07%
Cost of Revenue13.67M29.91M73.03M100.53M156.87M189.41M8.47M8.85M185.94M9.66M
Gross Profit-13.26M-26.18M27.68M21.22M21.10M207.09M133.62M88.21M-85.38M11.38M
Gross Margin-3187.02%-700.83%100.00%100.00%100.00%100.00%100.00%90.88%-84.91%54.09%
Operating Expense1.87M6.50M84.97M135.62M216.27M244.44M271.45M239.95M59.62M157.19M
Operating Income-15.13M-32.68M-57.29M-114.40M-195.17M-37.36M-137.83M-151.74M-145.00M-145.81M
Operating Margin-3637.50%-874.94%-206.99%-539.16%-925.08%-18.04%-103.16%-156.33%-144.19%-692.83%
EBITDA-14.93M-32.00M-56.27M-108.83M-187.91M-29.05M-129.36M-116.33M-110.08M-133.10M
EBITDA Margin-3589.18%-856.73%-203.31%-512.89%-890.65%-14.03%-96.82%-119.85%-109.47%-632.45%
Net Income-15.11M-32.48M-52.25M-99.81M-182.96M-28.01M-133.31M-130.39M-119.05M-142.93M
Net Income Margin-3632.21%-869.61%-188.78%-470.39%-867.21%-13.53%-99.77%-134.34%-118.39%-679.16%
R&D13.67M29.91M73.03M100.53M156.87M189.41M210.42M192.12M209.24M123.06M
R&D as % of Total Revenue3287.02%800.83%263.87%473.76%743.53%91.46%157.48%197.93%208.08%584.77%
Interest Expense000008.31M16.25M---
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%4.02%12.16%---

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets54.11M236.06M308.36M421.91M488.25M814.66M787.65M621.83M468.30M293.24M
Total Liabilities79.02M288.09M405.76M227.17M220.72M513.93M573.21M487.67M341.50M262.59M
Total Equity-24.91M-52.03M-97.40M194.74M267.53M300.72M214.44M134.16M126.80M30.65M
Cash50.84M32.45M65.47M89.64M49.97M329.15M154.32M74.56M33.02M65.80M
Total Debt---48.04M51.26M47.60M43.33M38.92M42.52M36.23M
Net Debt-50.84M-32.45M-65.47M-41.60M1.29M-281.55M-111.00M-35.64M9.50M-29.57M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-12.99M-17.77M127.46M-99.31M-166.73M298.55M-20.33M-184.16M-229.91M-184.03M
Investing Cash Flow-2.25M-801.00K-224.12M-48.87M-105.05M-49.66M-159.01M101.92M107.13M196.60M
Financing Cash Flow-77.00K-15.00K131.15M172.35M232.11M30.30M4.51M2.55M81.54M20.21M
Capital Expenditure2.25M801.00K1.88M15.27M5.03M3.25M4.12M2.38M1.25M41.00K
Free Cash Flow-15.24M-18.57M125.58M-114.57M-171.77M295.30M-24.45M-186.54M-231.16M-184.07M
FCF to OCF117.32%104.51%98.52%115.37%103.02%98.91%120.25%101.29%100.55%100.02%

Earnings

Report DateOct 12, 2018Mar 26, 2019May 13, 2019Aug 12, 2019Nov 12, 2019Mar 24, 2020May 13, 2020Aug 11, 2020Nov 10, 2020Feb 25, 2021May 5, 2021Aug 3, 2021Nov 4, 2021Feb 24, 2022May 5, 2022Aug 4, 2022Nov 8, 2022Feb 28, 2023May 4, 2023Aug 3, 2023Nov 7, 2023Feb 27, 2024May 8, 2024Aug 7, 2024Nov 6, 2024Feb 25, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Mar 3, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.00-0.28-0.31-0.32-0.40-0.44-0.43-0.50-0.55-0.66-0.67-0.692.83-0.190.17-0.44-0.51-0.46-0.78-0.82-0.65-0.77-0.49-0.48-0.53-0.54-0.46-0.45-0.41-0.39-0.27-0.24-0.25
EPS Actual-0.29-1.48-0.27-0.36-0.47-0.45-0.53-0.58-0.67-0.66-0.66-0.691.49-0.68-0.540.12-0.56-0.63-0.550.02-0.53-0.49-0.38-0.40-0.43-0.02-0.41-0.30-0.34-0.34-0.21-0.21-
Surprise--428.57%12.90%-12.50%-17.50%-2.27%-23.26%-16.00%-21.82%0.00%1.49%0.00%-47.35%-257.89%-417.65%127.27%-9.80%-36.96%29.49%102.44%18.46%36.36%22.45%16.67%18.87%96.33%10.87%33.33%17.07%13.11%22.22%12.50%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap217.73M
Enterprise Value84.39M
Trailing P/E0.00
Forward P/E8.47
Price / Sales15.71
Price / Book19.57
EPS-1.03
Book Value-0.089
Revenue (TTM)13.86M
Gross Profit (TTM)-85.27M
EBITDA-119.03M
Profit Margin0.00%
Operating Margin-734.73%
Return on Equity-385.11%
Return on Assets-27.62%
Shares Outstanding111.66M
Shares Float89.41M
Beta0.65
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 9 analystsTarget 3.10
  • Strong Buy
    5
  • Buy
    1
  • Hold
    1
  • Sell
    1
  • Strong Sell
    1

Ownership Breakdown

Institutions
93.29%
Insiders
9.52%
Retail / Other
0.00%

Top Institutional Holders

  • TCG Crossover Management, LLC
    10.00M8.96%
  • BlackRock Inc
    7.74M6.93%
  • Acadian Asset Management LLC
    4.04M3.62%
  • Kynam Capital Management, LP
    3.81M3.41%
  • Vanguard Capital Management, LLC
    3.68M3.29%
  • Merck & Co Inc
    3.55M3.18%
  • 683 Capital Management LLC
    3.20M2.87%
  • D. E. Shaw & Co LP
    2.96M2.65%
  • Balyasny Asset Management LLC
    2.94M2.63%
  • Nantahala Capital Management, LLC
    2.82M2.52%
  • Vanguard Portfolio Management, LLC
    2.58M2.31%
  • Geode Capital Management, LLC
    2.29M2.05%
  • Jacobs Levy Equity Management, Inc.
    2.15M1.93%
  • Spruce Street Capital LP
    2.10M1.88%
  • Ikarian Capital, LLC
    2.08M1.87%
  • Millennium Management LLC
    1.99M1.78%
  • State Street Corp
    1.87M1.67%
  • FMR Inc
    1.80M1.61%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.84M2.54%
  • iShares Russell 2000 ETF
    2.51M2.25%